Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Can Tyson's (TSN) Q3 Earnings Help Continue Its Stellar Year?

Published 08/01/2019, 11:34 PM
Updated 07/09/2023, 06:31 AM

Tyson (NYSE:TSN) is set to report its Q3 2019 (Tyson ends its fiscal year after September) earnings results before market open on Monday, August 5. YTD, the stock has gained over 51%, significantly outperforming both the S&P 500 and the meats product market which have gained 16.4% and 27.4%, respectively.

Overview & Fundamentals

Based in Arkansas, Tyson Inc. is the second largest meat processor in the world as of 2018. Tyson sells its meat through its own brand and multiple other popular brands such as Jimmy Dean, Hillshire Farm, Sara Lee, and Ball Park.

Along with selling its meats in retail stores such as Walmart (NYSE:WMT) and Kroger (NYSE:KR) , Tyson also sells its offerings to chain restaurants such as KFC and Taco Bell, which are owned by Yum! Brands (NYSE:YUM) , as well as McDonalds (NYSE:MCD) . Tyson also recently began its efforts to enter the alternative meat market.

Tyson was an early investor in Beyond Meat (NASDAQ:BYND) , but sold its stake earlier this year in order to focus on its own alternative meat products. In June, Tyson announced it would roll out its Raised and Rooted brand, which featured plant-based nuggets and “blended burgers.” Although the products have yet to go on sale, Tyson may offer investors more information on the products and future alternative meat ideas.

TSN currently trades with a forward P/E of 12.61, significantly below its industry average of 15.68. This suggests that Tyson stock is relatively undervalued based on TSN’s impressive 2019 run and signals that its earnings outlook is headed in the right direction.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Q3 Outlook & Earnings Trends

Q3 revenue is expected to grow 10.51% from the year-ago period to $11.11 billion, according to our Zacks Consensus Estimate. Last quarter, Tyson posted revenue of $10.443 billion, for a 6.9% jump. Tyson’s revenues have continuously grown since 2007, and the company is not expected to stop anytime soon.

Tyson is expected to post total fiscal 2019 revenue of $42.90 billion, which would represent over 7% growth. An additional 5.92% growth is expected in fiscal 2020. This revenue growth could be even better if its alternative meat products end up being very successful.

In Q3, our Key Company Metrics call for Tyson’s chicken sales to increase over 26%, a huge jump for its second-biggest revenue stream. Tyson’s largest revenue stream, beef, is also expected to grow its revenue, although the 2% growth that is expected is significantly less than that of chicken. Overall, beef and chicken sales account for over 65% of Tyson’s total revenue.

Meanwhile, earnings are expected to decline by 2% this quarter and a total of 3% for fiscal 2019, giving quarterly and annual EPS of $1.47 and $5.97, respectively. Although earnings are expected to decline slightly this year, EPS is expected to rebound 9% in fiscal 2020, reaching $6.55, based on analyst predictions.

Bottom Line

As seen with the craze around Beyond Meat and Impossible Foods, alternative meats are trending right now and Tyson’s expansion into the market could prove to be a huge success and help the stock significantly. That being said, there is a little while before that is relevant to its financials, so investors should primarily keep an eye on Tyson’s top and bottom lines, as well as any updated guidance for the full fiscal year. If Tyson can continue to expand its revenues, its bottom line should catch up in terms of growth sooner or later.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>



Tyson Foods, Inc. (TSN): Free Stock Analysis Report

Walmart Inc. (WMT): Free Stock Analysis Report

McDonald's Corporation (MCD): Free Stock Analysis Report

Yum! Brands, Inc. (YUM): Free Stock Analysis Report

The Kroger Co. (KR): Free Stock Analysis Report

Beyond Meat, Inc. (BYND): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.